Drug Type Small molecule drug |
Synonyms Cenicriviroc/tropifexor, Tropifexor/Cenicriviroc, CVC/LJN452 + [1] |
Target |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists), CCR5 antagonists(C-C chemokine receptor type 5 antagonists), FXR agonists(Bile acid receptor FXR agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC42H56N4O7S2 |
InChIKeyIXPBPUPDRDCRSY-YLZLUMLXSA-N |
CAS Registry497223-28-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
MASH | Phase 2 | US | 01 Aug 2016 | |
MASH | Phase 2 | JP | 01 Aug 2016 | |
MASH | Phase 2 | AR | 01 Aug 2016 | |
MASH | Phase 2 | AU | 01 Aug 2016 | |
MASH | Phase 2 | AT | 01 Aug 2016 | |
MASH | Phase 2 | BE | 01 Aug 2016 | |
MASH | Phase 2 | CA | 01 Aug 2016 | |
MASH | Phase 2 | FR | 01 Aug 2016 | |
MASH | Phase 2 | DE | 01 Aug 2016 | |
MASH | Phase 2 | IN | 01 Aug 2016 |